What is the prevalence of Polymyalgia Rheumatica?

Polymyalgia rheumatica is a common inflammatory condition primarily affecting individuals over age 50, with an estimated prevalence of approximately 500 to 700 per 100,000 people in Western populations. While not classified as a "rare" disease, accurate global prevalence of polymyalgia rheumatica remains challenging to determine due to frequent misdiagnosis and symptom overlap with other rheumatic disorders.

Who is most affected by polymyalgia rheumatica?

Polymyalgia rheumatica shows a strong predilection for older adults; it is extremely rare in individuals under the age of 50, with the average age of onset typically occurring between 70 and 80. Epidemiological data indicates that females are approximately two to three times more likely to develop polymyalgia rheumatica than males. Furthermore, there is a notable geographic and ethnic variance, as the condition is significantly more common in individuals of Northern European descent compared to those of African or Asian ancestry.

What are the challenges in tracking polymyalgia rheumatica data?

Determining the exact incidence of polymyalgia rheumatica is complicated by several factors. Because its primary symptoms—stiffness and aching in the shoulders and hips—can mimic conditions like rheumatoid arthritis or fibromyalgia, many cases go underreported. Current clinical estimates suggest an annual incidence of 50 to 100 per 100,000 people in the over-50 population, though these figures may underrepresent the true burden of the disease.

Key epidemiological facts about polymyalgia rheumatica

• Age of onset: Rarely seen before age 50; peak incidence between 70–80 years.


• Gender ratio: Females are affected at a rate of 2:1 to 3:1 compared to males.


• Geographic trend: Highest prevalence observed in populations of Scandinavian and Northern European descent.


• Community insight: The DiseaseMaps.org community currently supports 52 individuals living with polymyalgia rheumatica, providing a vital platform for sharing real-world experiences that complement clinical data.

Next steps

• Consult a rheumatologist for a physical examination and inflammatory marker blood tests (ESR/CRP).


• Monitor for symptoms of giant cell arteritis, which is closely linked to polymyalgia rheumatica.


• Join the DiseaseMaps.org patient community to connect with others sharing their journey with the disease.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Polymyalgia rheumatica overview.


• Orphanet: Prevalence and epidemiology of systemic inflammatory rheumatic diseases.


• PubMed/NCBI: "Epidemiology of Polymyalgia Rheumatica: A systematic review."


• American College of Rheumatology: Clinical guidelines for the management of rheumatic conditions.